Administering aspirin, rivaroxaban and low-molecular-weight heparin to prevent deep venous thrombosis after total knee arthroplasty

Blood Coagulation and Fibrinolysis

Volumn 25, Issue 7, 2014, Pages 660-664

  Zou, Yue ^a   Tian, Shaoqi ^a   Wang, Yuanhe ^a   Sun, Kang ^a  

^a QINGDAO UNIVERSITY   (China)

Author keywords

Aspirin; Low molecular weight heparin; Rivaroxaban; Total knee arthroplasty; Venous thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; HEMOGLOBIN; LOW MOLECULAR WEIGHT HEPARIN; RIVAROXABAN; MORPHOLINE DERIVATIVE; THIOPHENE DERIVATIVE;

ADULT; ADVERSE OUTCOME; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BLOOD VOLUME; COLOR ULTRASOUND FLOWMETRY; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; ECCHYMOSIS; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; KNEE SOCIETY SCORE; LIMB SWELLING; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PATIENT MONITORING; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS ECCHYMOSIS; THROMBOSIS PREVENTION; TOTAL KNEE REPLACEMENT; TREATMENT OUTCOME; VERY ELDERLY; WOUND COMPLICATION; WOUND HEALING; ADVERSE EFFECTS; KNEE ARTHROPLASTY; PROCEDURES; VENOUS THROMBOSIS;

AGED; AGED, 80 AND OVER; ARTHROPLASTY, REPLACEMENT, KNEE; ASPIRIN; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; MIDDLE AGED; MORPHOLINES; PROSPECTIVE STUDIES; THIOPHENES; VENOUS THROMBOSIS;

EID: 84921753563     PISSN: 09575235     EISSN: 14735733     Source Type: Journal    
DOI: 10.1097/MBC.0000000000000121     Document Type: Article

References (20)

1. Quinlan DJ, Eikelboom JW, Dahl OE, Eriksson BI, Sidhu PS, Hirsh J, et al. Association between asymptomatic deep vein thrombosis detected by venography and symptomatic venous thromboembolism in patients undergoing elective hip or knee surgery. J Thromb Haemost 2007; 5:1438-1443.
2. Howie C, Hughes H, Watts AC. Venous thromboembolism associated with hip and knee replacement over a ten-year period: a population-based study. J Bone Joint Surg Br 2005; 87-B:1675-1680.
3. Jameson SS, Rymaszewska M, Hui AC, James P, Serrano-Pedraza I, Muller SD, et al. Wound complications following rivaroxaban administration: a multicenter comparison with low-molecular-weight heparins for thromboprophylaxis in lower limb arthroplasty. J Bone Joint Surg Am 2012; 94:1554-1558.
4. Gomez-Outes A, Terleira-Fernandez AI, Suarez-Gea ML, Vargas-Castrillon E. Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons. BMJ 2012; 344:e3675.
5. Bozic KJ, Vail TP, Pekow PS, Maselli JH, Lindenauer PK, Auerbach AD. Does aspirin have a role in venous thromboembolism prophylaxis in total knee arthroplasty patients? J Arthroplasty 2010; 25:1053-1060.
6. Brown GA. Venous thromboembolism prophylaxis after major orthopaedic surgery: a pooledanalysis of randomized controlled trials. J Arthroplasty 2009; 24 (6 Suppl):77-83.
7. Kilicarslan K, Yalcin N, Cicek H, Dogramaci Y, Ugurlu M, Ozkan H, Yildirim H. The effect of total synovectomy in total knee arthroplasty: a prospective randomized controlled study. Knee Surg Sports Traumatol Arthrosc 2011; 19:932-935.
8. Insall JN, Dorr LD, Scott RD, Scott WN. Rationale of the Knee Society clinical rating system. Clin Orthop Relat Res 1989; 248: 13-14.
9. Cross JB. Estimating allowable blood loss: corrected for dilution. Anesthesiology 1983; 58:277-280.
10. Sehat KR, Evans R, Newman JH. How much blood is really lost in total knee arthroplasty? Correct blood loss management should take hidden loss into account. The Knee 2000; 7:151-155.
11. Nadler SB, Hidalgo JH, Bloch T. Prediction of blood volume in normal human adults. J Surg 1962; 51:224-232.
12. Fassiadis N. Rivaroxaban: direct factor Xa inhibition totreat acute deep vein thrombosis. Br J Hosp Med (Lond) 2011; 72:486.
13. Alves C, Batel-Marques F, Macedo AF. Apixaban and rivaroxaban safety after hip and knee arthroplasty: a meta-analysis. J Cardiovasc Pharmacol Ther 2012; 17:266-276.
14. Zhao X, Sun P, Zhou Y, et al. Safety, pharmacokinetics and pharmacodynamics of single/multiple doses of the oral, direct Factor Xa inhibitor rivaroxaban in healthy Chinese subjects. Brit J Clin Pharmacol 2009; 68:77-88.
15. Pattison E, Protheroe K, Pringle RM, Kennedy AC, Dick WC. Reduction in haemoglobin after knee joint surgery. Ann Rheum Dis 1973; 32:582-584.
16. Prasad N, Padmanabhan V, Mullaji A. Blood loss in total knee arthroplasty: an analysis of risk factors. Int Orthop 2007; 31:39-44.
17. CateUa-Lawson F. Vascular biology of thrombosis: platelet-vessel wall interactions and aspirin effects. Neurology 2001; 57:5-7.
18. Jameson SS, Baker PN, Charman SC, Deehan DJ, Reed MR, Gregg PJ, Van der Meulen JH. The effect of aspirin and low-molecular-weight heparin on venous thromboembolism after knee replacement: A nonrandomized comparison using National Joint Registry Data. J Bone Joint Surg Br 2012; 94:914-918.
19. Lotke PA, Lonner JH. The Benefit of aspirin chemoprophylaxis for thromboembolism after total knee arthroplasty. Clini Orthop Relat Res 2006; 452:175-180.
20. Lotke PA. The role of aspirin for thromboembolic disease in total joint arthmplasty. Am J Knee Surg 1999; 12:61-63.